Forest plot of 5-year overall survival rates for RCTs and non-RCTs.
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology
Cancers | Free Full-Text | Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer
Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007) | SpringerLink
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project | Blood Cancer Journal
VENCLEXTA® (venetoclax tablets) | Additional Follow-up Data for CLL/SLL
Overall Survival After 5 Years in Patients With Locally Advanced SCCHN Treated With Xevinapant Plus Chemoradiotherapy vs Placebo Plus CRT | PracticeUpdate
Survival curve. The 5-year progression free survival and overall... | Download Scientific Diagram
Overall survival. a The 5-year overall survival (OS) was 64.9%. b The... | Download Scientific Diagram
Alternative endpoints to the 5‑year overall survival and locoregional control for nasopharyngeal carcinoma: A retrospective analysis of 2,450 patients
5-year Overall Survival Rates by Stage at Presentation | Download Scientific Diagram
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology
Long-term survival and stage I breast cancer subtypes - ScienceDirect
Expression profile analysis identifies a two-gene signature for prediction of head and neck squamous cell carcinoma patient survival Xu X, Li M, Hu J, Chen Z, Yu J, Dong Y, Sun C,
![PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7cbf64e0a2a5bc6572dc331e433efae660922309/4-Figure1-1.png "PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar")
PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar
This figure shows the 5-year overall survival (OS) in 250 synovial... | Download Scientific Diagram
5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO
Study shows survival benefits of smoking cessation after lung cancer diagnosis
P48.05 Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC? - Journal of Thoracic Oncology
Five-year overall survival by era. (A) Kaplan-Meier estimates of OS... | Download Scientific Diagram
5-year overall survival rates of Different Tumor Stages. After Log-rank... | Download Scientific Diagram
Efficacy for Newly Diagnosed Glioblastoma (GBM) | Optune®
Overall survival curve by treatment method. The 5-year overall survival... | Download Scientific Diagram
survival - 5-year EFS > 5-year OS - Cross Validated
